Posttransplant Lymphoproliferative Disorders in Cardiac Transplant Patients

This publication has 19 references indexed in Scilit:

• Production of Genetically Modified Epstein-Barr Virus-Specific Cytotoxic T Cells for Adoptive Transfer to Patients at High Risk of EBV-Associated Lymphoproliferative Disease
  Journal of Hematotherapy, 1995
• Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation
  New England Journal of Medicine, 1994
• Management of lymphoproliferative disorders after cardiac transplantation
  The Annals of Thoracic Surgery, 1993
• Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death
  Cell, 1991
• Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ Transplantation
  New England Journal of Medicine, 1991
• Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients
  New England Journal of Medicine, 1990
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
  Nature, 1990
• Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: Two cases of after solid organ transplantation
  The American Journal of Medicine, 1989
• Treatment of B-Cell Lymphoproliferative Disorders with Interferon Alfa and Intravenous Gamma Globulin
  New England Journal of Medicine, 1988
• Epstein–Barr Virus-Induced B-Cell Lymphoma after Renal Transplantation
  New England Journal of Medicine, 1982